Michael Daley

Michael Daley

Auto-generated profile, based on publicly available information

Michael Daley

Department of Cardiac Surgery, The Royal Children's Hospital, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2019 in Heart
Verified
Journal Article
Closed access
PDF file
MDMichael Daley
Michael Daley
KPKarin du Plessis
Karin du Plessis
DZDianna Zannino
Dianna Zannino
THTim Hornung
Tim Hornung
PDPatrick Disney
Patrick Disney
YDYves D'UDekem
Yves D'UDekem
Objective Patients undergoing single-ventricle palliation have experienced significant improvement in survival in the recent era. However, a substantial proportion of these patients undergo reoperations. We performed a review of the Australia and New Zealand (ANZ) Fontan Registry to determine the overall reintervention and reoperative burden in these patients. Methods A retrospective longitudinal cohort study was performed using data from patients who underwent a Fontan operation between 1975 and 2016 from the ANZ Fontan Registry. The data obtained included Fontan operation, reinterventions and most recent follow-up status. We examined the type and timing of reinterventions and survival. Results Of the 1428 patients identified, 435 (30%) underwent at least one reintervention after the Fontan operation: 110 patients underwent early reintervention and 413 underwent late reinterventions. Excluding Fontan conversion and transplantation, 220 patients underwent at least one interventional procedure and 209 patients underwent at least one reoperation. Fenestration closure and pacemaker-related procedures were the most common catheter and surgical interventions, respectively. The cumulative incidence of reintervention following Fontan was 23%, 37% and 55% at 10, 20 and 30 years, respectively. Survival and freedom from failure were worse in patients requiring later reintervention after Fontan surgery (51% vs 83% and 42% vs 69%, respectively at 30 years, p<0.001). This difference persisted after excluding pacemaker-related procedures (p<0.001). Operative mortality for non-pacemaker late reoperations after Fontan was 6%. Conclusions A substantial proportion of Fontan patients require further intervention to maintain effective single-ventricle circulation. Patients undergoing reoperation after Fontan have higher rates of mortality and failure, despite intervention.

7 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MDMichael Daley
Michael Daley
EBEdward Buratto
Edward Buratto
GKGregory King
Gregory King
LGLeeanne Grigg
Leeanne Grigg
AIAjay Iyengar
Ajay Iyengar
IKIgor E. Konstantinov
Igor E. Konstantinov
Background: The long‐term impact of fenestration at the time of Fontan operation remains unclear. We aimed to review the early and long‐term impact of Fontan fenestration in the Australia and New Zealand cohort. Methods and Results: We reviewed 1443 patients (621 fenestrated, 822 nonfenestrated) from the Australia and New Zealand Fontan registry. Data were collected on preoperative demographics, operative details, and follow‐up. Propensity‐score matching was performed to account for the various preoperative and operative differences and risk factors. Primary outcomes were survival and freedom from failure. Median follow‐up was 10.6 years. After propensity‐score matching (407 matched pairs), there was no difference in survival (87% versus 90% at 20 years; P =0.16) or freedom from failure (73% versus 80% at 20 years; P =0.10) between patients with and without fenestration, respectively. Although patients with fenestration had longer bypass and cross‐clamp times ( P <0.001), there was no difference in hospital length of stay or prolonged pleural effusions ( P =0.80 and P =0.46, respectively). Freedom from systemic and Fontan circuit thromboembolism was higher in the nonfenestrated group (89%; 95% CI, 88%–95%) than the fenestrated group (84%; 95% CI, 77%–89%; P =0.03). There was no difference in incidence of plastic bronchitis, protein‐losing enteropathy, New York Heart Association Class III/IV symptoms, or Fontan takedown. Conclusions: In the propensity score–matched analysis we have demonstrated no difference in long‐term survival or freedom from Fontan failure in patients with and without fenestration. There was a higher incidence of long‐term thromboembolic events in patients with fenestration. Overall, it appears that fenestration in Fontan circulation does not bring long‐term benefits.

1 July 2020 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
TFTyson A. Fricke
Tyson A. Fricke
DBDouglas Bell
Douglas Bell
MDMichael Daley
Michael Daley
YDYves D'UDekem
Yves D'UDekem
CBChristian P. Brizard
Christian P. Brizard
IKIgor E. Konstantinov
Igor E. Konstantinov

29 January 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
NPNischal R Pandya
Nischal R Pandya
MDMichael Daley
Michael Daley
AMAdrian Mattke
Adrian Mattke
FSFumiaki Shikata
Fumiaki Shikata
KBKim Betts
Kim Betts
PVPrem Venugopal
Prem Venugopal
OBJECTIVES: The aim of the study is to compare a technique of pump-controlled retrograde trial off (PCRTO) to insertion of an arterio-venous (AV) bridge to conduct a trial from venoarterial extracorporeal membrane oxygenation (VA ECMO). METHODS: We studied all patients who were weaned from VA ECMO using either PCRTO or AV bridging from November 2014 to April 2018. Demographic data, indications for ECMO, duration of ECMO, duration of trial period off ECMO and survival were compared between the 2 groups. RESULTS: Seventy-nine patients were placed on VA ECMO from November 2014 to April 2018, of whom, 51 (65%) patients met the study inclusion criteria: 31 (61%) patients who had a trial period from VA ECMO using PCRTO and 20 (39%) patients who were weaned using an AV bridge. The indications for ECMO included cardiac (n = 16 and 11, respectively) and non-cardiac aetiologies (n = 15 and 9, respectively). There was 1 death in each group. The duration of the trial off VA ECMO was significantly shorter in the PCRTO group (median = 88.0 vs 196.6 min, P < 0.001). There were 2 conversions from PCRTO to AV bridging during the trial period off ECMO (2.9-kg neonate following a Norwood procedure and 2.2-kg patient following repair of ectopia cordis). CONCLUSIONS: PCRTO is a safe, simple and reproducible approach for enabling a trial period while preserving the circuit during weaning from VA ECMO. In our study, the duration of the trial period off VA ECMO was significantly shorter in the PCRTO group. PCRTO avoids manipulation of the ECMO circuit, provides a ‘stress test’ to evaluate cardiorespiratory reserve during the trial period off ECMO, is applicable for a wide variety of cardiac and non-cardiac indications and facilitates multiple attempts at weaning from ECMO.

1 July 2018 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
EBEdward Buratto
Edward Buratto
BKBrandon Khoo
Brandon Khoo
XYXin Tao Ye
Xin Tao Ye
MDMichael Daley
Michael Daley
CBChristian P. Brizard
Christian P. Brizard
IKIgor E. Konstantinov
Igor E. Konstantinov

1 December 2017 in Heart
Verified
Journal Article
Closed access
PDF file
EBEdward Buratto
Edward Buratto
MDMichael Daley
Michael Daley
XYXin Tao Ye
Xin Tao Ye
DRDorothy J Radford
Dorothy J Radford
Nelson AlphonsoNelson Alphonso
Nelson Alphonso
IKIgor E Konstantinov
Igor E Konstantinov
Objective Partial atrioventricular septal defect (pAVSD) is usually repaired between 2 and 4 years of age with excellent results. Repair during infancy has been associated with poorer outcomes. However, most infants in reported series had heart failure or significant left atrioventricular valve (LAVV) regurgitation. The impact of surgery during infancy on outcomes remains unclear. Methods All children at three institutions who underwent repair of pAVSD from 1975 to 2015 were included. Infants (aged <1 year) were compared with older children in a propensity score matched analysis. Variables used to generate propensity scores were: failure to thrive, congestive heart failure, preoperative LAVV regurgitation, associated congenital heart disease, sex and the presence of trisomy 21. Results pAVSD repair was performed on 430 children, 17.4% (75/430) were infants. Infants (mean age 0.5±0.3 years) had higher rates of LAVV regurgitation, heart failure and additional cardiac malformations than older children (mean age 4.7±3.5 years). At 30 years, survival for infants was 82.1% (95% CI 70.1% to 89.6%) compared with 95.7% (95% CI 91.3% to 97.9%) in older children (P<0.001). Propensity score matching yielded 52 well-matched pairs. Survival at 30 years was 87.9% (95% CI 75.0% to 94.4%) for infants compared with 98.1% (95% CI 87.1% to 99.7%) for older children (P=0.04). There was no significant difference in freedom from reoperation between the groups. Conclusions Despite matching for risk factors, survival after repair of pAVSD during infancy is lower than that when repair is performed in older children, with no difference in reoperation rates. This suggests that elective repair of pAVSD should be deferred until after infancy.